Ziccum AB — Investor Relations & Filings

Ziccum AB is a pharmaceutical technology company that has developed LaminarPace®, a patented ambient drying system. This technology utilizes mass transfer, rather than heat, to convert liquid biologics into thermostable, particle-engineered powders. The process is designed to gently dry sensitive biopharmaceuticals, including next-generation vaccines such as mRNA, adenovirus vectors, and adjuvanted vaccines, without causing heat degradation. The resulting dry-powder formulations are stable at room temperature, eliminating the need for cold-chain transportation and storage, and are suitable for novel administration routes. Ziccum's business model focuses on offering licenses and technology transfers to vaccine and biopharmaceutical companies.